Treatment of Patients With MDS or AML With an Impending Hematological Relapse With Azacitidine (Vidaza)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 16 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary)
Indications Acute myeloid leukaemia; Myelodysplastic syndromes
Focus Therapeutic Use
Acronyms RELAZA2

Most Recent Events

08 Dec 2020 Status changed to completed as per results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
06 Nov 2019 Results released at the 61st Annual Meeting and Exposition of the American Society of Hematology

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight